Literature DB >> 11262404

Increased sensitivity of transforming growth factor (TGF) beta 1 null cells to alkylating agents reveals a novel link between TGFbeta signaling and O(6)-methylguanine methyltransferase promoter hypermethylation.

H Yamada1, K Vijayachandra, C Penner, A Glick.   

Abstract

Inactivation of the transforming growth factor beta (TGFbeta)-signaling pathway and gene silencing through hypermethylation of promoter CpG islands are two frequent alterations in human and experimental cancers. Here we report that nonneoplastic TGFbeta1-/- keratinocyte cell lines exhibit increased sensitivity to cell killing by alkylating agents, and this is due to lack of expression of the DNA repair enzyme O(6)-methylguanine DNA methyltransferase (MGMT). In TGFbeta1-/- but not TGFbeta1+/- cell lines, the CpG dinucleotides in the MGMT promoter are hypermethylated, as measured by restriction enzyme analysis and methylation specific polymerase chain reaction. In one unstable TGFbeta1+/- cell line, loss of the wild type TGFbeta1 allele correlates with the appearance of methylation in the MGMT promoter. Bisulfite sequencing shows that in the KO3 TGFbeta1-/- cell line nearly all of the 28 CpG sites in the MGMT promoter 475 base pairs upstream of the start site of transcription are methylated, whereas most are unmethylated in the H1 TGFbeta1+/- line. Treatment of the TGFbeta1-/- cell lines with 5-azacytidine causes reexpression of MGMT mRNA and demethylation of CpG islands in the promoter. Analysis of the time course of methylation using methylation-specific polymerase chain reaction shows a lack of methylation in primary TGFbeta1-/- keratinocytes and increasing methylation with passage number of immortalized clones. Subcloning of early passage clones reveals a remarkable heterogeneity and instability of the methylation state in the TGFbeta1-/- keratinocytes. Thus, the TGFbeta1-/- genotype does not directly regulate MGMT methylation but predisposes cells to immortalization-associated MGMT hypermethylation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11262404     DOI: 10.1074/jbc.M100615200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery.

Authors:  Brett L Carlson; Jenny L Pokorny; Mark A Schroeder; Jann N Sarkaria
Journal:  Curr Protoc Pharmacol       Date:  2011-03

2.  Detection of genomic DNA methylation with denaturing high performance liquid chromatography.

Authors:  Romaica A Omaruddin; M Ahmad Chaudhry
Journal:  Hum Cell       Date:  2010-05       Impact factor: 4.174

3.  Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.

Authors:  Gaspar J Kitange; Brett L Carlson; Ann C Mladek; Paul A Decker; Mark A Schroeder; Wenting Wu; Patrick T Grogan; Caterina Giannini; Karla V Ballman; Jan C Buckner; C David James; Jann N Sarkaria
Journal:  J Neurooncol       Date:  2008-11-15       Impact factor: 4.130

4.  Interleukin-1β increases the risk of gastric cancer through induction of aberrant DNA methylation in a mouse model.

Authors:  Fung-Yu Huang; Annie On-On Chan; Asif Rashid; Danny Ka-Ho Wong; Wai-Kay Seto; Chi-Hin Cho; Ching-Lung Lai; Man-Fung Yuen
Journal:  Oncol Lett       Date:  2016-03-01       Impact factor: 2.967

5.  TGF-β mediated DNA methylation in prostate cancer.

Authors:  Chung Lee; Qiang Zhang; Xaolin Zi; Atreya Dash; Marcelo B Soares; Farahnaz Rahmatpanah; Zhenyu Jia; Michael McClelland; Dan Mercola
Journal:  Transl Androl Urol       Date:  2012-06

6.  Long noncoding RNA RP11-838N2.4 enhances the cytotoxic effects of temozolomide by inhibiting the functions of miR-10a in glioblastoma cell lines.

Authors:  Yanting Liu; Ningbo Xu; Boyang Liu; Yiru Huang; Huijun Zeng; Zhao Yang; Zhenyan He; Hongbo Guo
Journal:  Oncotarget       Date:  2016-07-12

7.  Viability fingerprint of glioblastoma cell lines: roles of mitotic, proliferative, and epigenetic targets.

Authors:  Darja Lavogina; Tõnis Laasfeld; Markus Vardja; Helen Lust; Jana Jaal
Journal:  Sci Rep       Date:  2021-10-13       Impact factor: 4.379

8.  TAK1 mRNA expression in the tumor tissue of locally advanced head and neck cancer patients.

Authors:  Beatriz Honorato; Juan Alcalde; Rafael Martinez-Monge; Natalia Zabalegui; Jesús Garcia-Foncillas
Journal:  Gene Regul Syst Bio       Date:  2008-02-14

9.  Diet-induced obesity modulates epigenetic responses to ionizing radiation in mice.

Authors:  Guillaume Vares; Bing Wang; Hiroko Ishii-Ohba; Mitsuru Nenoi; Tetsuo Nakajima
Journal:  PLoS One       Date:  2014-08-29       Impact factor: 3.240

10.  Establishment and Characterisation of Heterotopic Patient-Derived Xenografts for Glioblastoma.

Authors:  Sarah Meneceur; Annett Linge; Matthias Meinhardt; Sandra Hering; Steffen Löck; Rebecca Bütof; Dietmar Krex; Gabriele Schackert; Achim Temme; Michael Baumann; Mechthild Krause; Cläre von Neubeck
Journal:  Cancers (Basel)       Date:  2020-04-03       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.